Therapeutic Advances in Chronic Disease
Share

Therapeutic Advances in Chronic Disease


Editor
Gordon Mallarkey SAGE Publications Ltd, UK
Associate Editors
Ian Beales Norfolk and Norwich University Hospital, Norfolk, UK
Emma Clark University of Bristol, Bristol, UK
George Perry The University of San Antonio, USA
Riccardo Polosa Az. Ospedaliero-Universitaria Vittorio Emanuele, Italy
Shahrad Taheri Weill Cornell Medical College, Doha, Qatar

eISSN: 20406231| ISSN: 20406223|Current volume: 6|Current issue: 1 Frequency: Bi-monthly

Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases (excluding cancer). You can access the journal online for free at www.sagepub.com/taj.

The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across areas of drug treatment of all major chronic diseases (excluding cancer, which is covered in Therapeutic Advances in Medical Oncology).

It publishes expert opinion reviews (including single-drug and drug class reviews), narrative reviews and analysis of published guidelines (as editorials or reviews). Original research manuscripts of well-designed trials are also welcomed that show drug or drug class efficacy in a particular disease or therapeutic area. The journal strongly encourages the submission of original research with positive or negative results.

The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees - a first editorial decision is generally reached within 3 weeks of submission. Online publication of articles occurs within 7 weeks from acceptance. Further information for contributors is provided on the back pages of each issue and online.

For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:
Commercial Sales Team, London, UK
Tel. +44 20 7336 1205
Email: reprints@sagepub.co.uk

This journal is a member of the Committee on Publication Ethics (COPE).

Therapeutic Advances in Chronic Disease covers the drug treatment of all major chronic diseases (excluding cancer, which is covered in a sister publication).

It publishes guidance on which drugs to use and when (i.e. expert opinion reviews, narrative reviews, analysis of published guidelines (editorials or reviews). Single-drug reviews (including brief reviews of new drugs) and drug class reviews are also published with the aim of providing practically relevant information to the doctor group that treats such patients.

Original research manuscripts of well-designed trials are also welcomed that show drug or drug class efficacy in a particular disease.

The journal adheres to a blinded review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees - a first editorial decision is generally reached within 3 weeks of submission. Further information for contributors are provided on the back pages of each issue.

1. The purpose of the Journal is to publish (in the English language) editorials, reviews and original research articles, that have been judged worthy of publication by appropriate specialists and accepted by the Editor-in-Chief, on clinical studies relating to chronic disease. The Journal is for all professionals with special expertise or interest in chronic disease treatment and management, and is a forum for all views on this subject. The Editor-in-Chief welcomes articles of current interest on original research and reviews.

2. The Journal will be international in the sense that it will seek, wherever possible, to publish material from authors with an international reputation and articles that are of interest to an international audience.

3. In pursuit of the above the journal shall:

(i) draw on and include high quality work from the international community of scholars including those in the major countries of Europe, Australasia, the United States, other parts of the Americas, countries in the Third World and elsewhere with due representation for considerations of the readership. The Journal shall include work representing the major areas of interest in contemporary research in chronic disease.

(ii) avoid bias in favour of the interests of particular schools or directions of research or particular political or narrow disciplinary objectives to the exclusion of others;

(iii) ensure that articles are written in a terminology and style which makes them intelligible, not merely within the context of a particular discipline or abstract mode, but across the domain of relevant disciplines.

Editorial Board
Kathryn Abel University of Manchester, UK
Bo Abrahamsen Copenhagen University Hospital Gentofte, Hellerup, Denmark
Frazer H Anderson Southampton University, UK
Riitta Antikainen Oulu City Hospital, Finland
Jonathan Bayly University of Derby, Derby, UK
Michael Berk University of Melbourne, Australia
Michael Blackburn University of Texas, USA
Xavier Calvet Hospital de Sabadell, Spain
Rudolph Castellani University of Maryland, USA
Gemma Casadesus Case Western Reserve University, USA
Mario Cazzola University of Rome "Tor Vergata", Rome, Italy
Pascal Chanez University of the Mediterranian, France
Emma Clark University of Bristol, Bristol, UK
Martin Connolly University of Auckland, New Zealand
Leonardo M. Fabbri University of Modena and Reggio Emilia, Italy
Serge Ferrari Hopitaux Universitaires de Geneve, Switzerland
Andrea Fox Chemical Abstracts Service, USA
Stephen Gallacher Southern General Hospital, Scotland
Javier P. Gisbert La Princesa University Hospital, Spain
Neil Gittoes University Hospitals Birmingham, UK
Nicola A Hanania Baylor College of Medicine, Houston, USA
Elaine Hylek Boston Medical Center, Boston, MA, USA
Peter Joyce Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
Hyoung-gon Lee Case Western Reserve University, Cleveland, OH, USA
Colleen Loo St George Hospital, Australia
Ricardo Maccioni University of Chile Medical School, Chile
Arduino Mangoni Flinders University, Adelaide, Australia
Tahir Masud Nottingham University, Nottingham, UK
Eugene McCloskey University of Sheffield, UK
Terry McCormack Whitby Medical Practice, UK
Andrew McIntosh University of Edinborgh, UK
Paula Moreira University of Coimbra, Portugal
Jaymin Morjaria University of Hull, Cottingham, UK
Bjorn Moum Faculty Div. Aker University Hospital, Norway
Anthony O'Conner Adelaide and Meath Hospital, Ireland
Pierluigi Paggiaro University of Pisa, Pisa, Italy
Sanjeev Patel St Helier University Hospital, UK
Ruth Peters Imperial College, London, UK
James B. Potash Mood Disorders Centre, USA
Craig Ritchie Imperial College London, UK
Shun Shinohama Sapporo Medical University, Japan
Thomas Schulze Georg-August-University Gvttingen , Germany
Massimo Tabaton University of Genoa, Genoa, Italy
Lakshmi Yatham University of British Columbia, Canada
Xiongwei Zhu Case Western Reserve University, USA
  • Chemical Abstracts Service (CAS)
  • Medscape
  • PubMed Central
  • SCOPUS
  • Please select a format:

    Individual, Single Print Issue

    £18.00
    $34.00

    Individual Subscription, Print Only

    £84.00
    $155.00

    Institutional, Single Print Issue

    £115.00
    $212.00

    Institutional Subscription, E-access

    £574.00
    $1,063.00

    Institutional Subscription, Print Only

    £625.00
    $1,157.00

    Institutional Subscription, Combined (Print & E-access)

    £638.00
    $1,181.00